A unique MUC1-2-VNTR DNA vaccine suppresses tumor growth and prolongs survival in a murine multiple myeloma model

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 1815-1822

  Weng, Yuhui ^a,c   Shao, Liang ^b   Ouyang, Hongmei ^a,e   Liu, Yuebo ^a   Yao, Jin ^a   Yang, Hong ^a   Luo, Yunjiao ^a,d   Wang, Hao ^a   Zhao, Zhenyu ^a   Mou, Hong ^a   Zhou, Zeping ^a   Zhang, You ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c Fuqing Hospital   (China)

^d Children's Hospital of Kunming   (China)

^e First People's Hospital of Yunnan   (China)

Author keywords

DNA vaccine; Mucin 1; Multiple myeloma; Variable number of tandem repeats

Indexed keywords

DNA VACCINE; MUCIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMORAL IMMUNITY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; CANCER VACCINES; CERCOPITHECUS AETHIOPS; COS CELLS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MINISATELLITE REPEATS; MUCIN-1; MULTIPLE MYELOMA; VACCINES, DNA;

EID: 84860708812     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1707     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 59: 225-249, 2009.
2. Patton S, Gendler SJ and Spicer AP: The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta 1241: 407-423, 1995. (Pubitemid 26021828)
3. Berois N, Varangot M, Aizen B, et al: Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR. Eur J Cancer 36: 717-723, 2000. (Pubitemid 30179742)
4. Seregni E, Botti C, Massaron S, et al: Structure, function and gene expression of epithelial mucins. Tumori 83: 625-632, 1997. (Pubitemid 27325971)
5. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J and Burchell J: A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263: 12820-12823, 1988.
6. Siddiqui J, Abe M, Hayes D, Shani E, Yunis E and Kufe D: Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci USA 85: 2320-2323, 1988. (Pubitemid 24315883)
7. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C and Taylor-Papadimitriou J: A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 43: 1072-1076, 1989. (Pubitemid 19158040)
8. Brossart P, Heinrich KS, Stuhler G, et al: Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93: 4309-4317, 1999. (Pubitemid 29279274)
9. Duperray C, Klein B, Durie BG, et al: Phenotypic analysis of human myeloma cell lines. Blood 73: 566-572, 1989. (Pubitemid 19060544)
10. Mark AS and Mangkornkanok M: B-cell lymphoma marking only with anti-epithelial membrane antigen. Cancer 63: 2152-2155, 1989.
11. Delsol G, Al Saati T, Gatter KC, et al: Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 130: 59-70, 1988. (Pubitemid 18044833)
12. Apostolopoulos V and McKenzie IF: Cellular mucins: targets for immunotherapy. Crit Rev Immunol 14: 293-309, 1994.
13. Finn OJ, Jerome KR, Henderson RA, et al: MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145: 61-89, 1995.
14. Barnd DL, Lan MS, Metzgar RS and Finn OJ: Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 86: 7159-7163, 1989. (Pubitemid 19240884)
15. Takahashi T, Makiguchi Y, Hinoda Y, et al: Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 153: 2102-2109, 1994. (Pubitemid 24256681)
16. Noto H, Takahashi T, Makiguchi Y, Hayashi T, Hinoda Y and Imai K: Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int Immunol 9: 791-798, 1997. (Pubitemid 27226403)
17. Taylor-Papadimitriou J and Epenetos AA: Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy. Trends Biotechnol 12: 227-233, 1994. (Pubitemid 24190550)
18. Nuti M, Rughetti A, Turchi V, Apollonj-Ghetti C, Scambia G and Frati L: Human B cell immune response to selected epitopes of the polymorphic epithelial mucin (PEM) in cancer patients. In Vivo 7: 645-647, 1993.
19. Sorensen AL, Reis CA, Tarp MA, et al: Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 16: 96-107, 2006. (Pubitemid 43125966)
20. Hareuveni M, Tsarfaty I, Zaretsky J, et al: A transcribed gene, containing a variable number of tandem repeats, codes for a human epithelial tumor antigen. cDNA cloning, expression of the transfected gene and over-expression in breast cancer tissue. Eur J Biochem 189: 475-486, 1990. (Pubitemid 20180418)
21. Lan MS, Batra SK, Qi WN, Metzgar RS and Hollingsworth MA: Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem 265: 15294-15299, 1990.
22. Merlo GR, Siddiqui J, Cropp CS, et al: Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas. Cancer Res 49: 6966-6971, 1989. (Pubitemid 20016576)
23. Silverman HS, Sutton-Smith M, McDermott K, et al: The contribution of tandem repeat number to the O-glycosylation of mucins. Glycobiology 13: 265-277, 2003. (Pubitemid 36592313)
24. Imai K: New mucin core protein genes and their clinical application. Hokkaido Igaku Zasshi 71: 139-143, 1996 (In Japanese).
25. Quinlin IS, Burnside JS, Dombrowski KE, Phillips CA, Dolby N and Wright SE: Context of MUC1 epitope: immunogenicity. Oncol Rep 17: 453-456, 2007.
26. Hilkens J, Kroezen V, Bonfrer JM, De Jong-Bakker M and Bruning PF: MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res 46: 2582-2587, 1986. (Pubitemid 16120735)
27. Delsol G, Gatter KC, Stein H, et al: Human lymphoid cells express epithelial membrane antigen. Implications for diagnosis of human neoplasms. Lancet 2: 1124-1129, 1984. (Pubitemid 15210848)
28. Sloane JP, Hughes F and Ormerod MG: An assessment of the value of epithelial membrane antigen and other epithelial markers in solving diagnostic problems in tumour histopathology. Histochem J 15: 645-654, 1983. (Pubitemid 13011787)
29. Choi C, Witzens M, Bucur M, et al: Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 105: 2132-2134, 2005. (Pubitemid 40731802)
30. Ding L, Lalani EN, Reddish M, et al: Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 36: 9-17, 1993.
31. Zhang S, Graeber LA, Helling F, et al: Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res 56: 3315-3319, 1996. (Pubitemid 26242982)
32. Gilewski T, Adluri S, Ragupathi G, et al: Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6: 1693-1701, 2000. (Pubitemid 30305061)
33. Soares MM, Mehta V and Finn OJ: Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 166: 6555-6563, 2001.
34. Westerlind U, Schroder H, Hobel A, et al: Tumor-associated MUC1 tandem-repeat glycopeptide microarrays to evaluate serum- and monoclonal-antibody specificity. Angew Chem Int Ed Engl 48: 8263-8267, 2009.
35. Acres B, Apostolopoulos V, Balloul JM, et al: MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 48: 588-594, 2000. (Pubitemid 30004493)
36. Scholl SM, Balloul JM, Le Goc G, et al: Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 23: 570-580, 2000.
37. Rochlitz C, Figlin R, Squiban P, et al: Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 5: 690-699, 2003. (Pubitemid 40309707)
38. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D and Gong J: Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 165: 5713-5719, 2000.
39. Gong J, Chen D, Kashiwaba M, et al: Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 95: 6279-6283, 1998. (Pubitemid 28249003)
40. Tanaka Y, Koido S, Chen D, Gendler SJ, Kufe D and Gong J: Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 101: 192-200, 2001.
41. Pecher G, Haring A, Kaiser L and Thiel E: Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51: 669-673, 2002. (Pubitemid 35446294)
42. Chen D, Xia J, Tanaka Y, et al: Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 109: 300-307, 2003. (Pubitemid 36683622)
43. Graham RA, Burchell JM, Beverley P and Taylor-Papadimitriou J: Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 65: 664-670, 1996. (Pubitemid 26092295)
44. Johnen H, Kulbe H and Pecher G: Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1). Cancer Immunol Immunother 50: 356-360, 2001. (Pubitemid 32835345)
45. + T cells but does not require the MUC1 tandem repeat domain. Int J Cancer 109: 691-697, 2004.
46. Tang DC, DeVit M and Johnston SA: Genetic immunization is a simple method for eliciting an immune response. Nature 356: 152-154, 1992.
47. Wei H, Zhang Y and Yang L: The expression of MUC1 gene in mm and its clinical significance. J Leukemia Lymphoma 14: 30-32, 2005 (In Chinese).
48. Yang H, Zhang Y, Yang L, Gao C and Wang X: The expression of MUC1 gene in hematological malignances and its clinical significance. J Leukemia Lymphoma 15: 438-441, 2006 (In Chinese).
49. Wang X, Zhang Y, Yang H, Gao C and Mou H: The expression of serum MUC1 in multiple myeloma. J Leukemia Lymphoma 17: 231-233, 2008 (In Chinese).
50. Kozak M: An analysis of 5'-non-coding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 15: 8125-8148, 1987.